STOCK TITAN

Lexeo Therapeutics CEO sells 3,295 shares to cover taxes

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) Chief Executive Officer Richard Nolan Townsend sold 3,295 shares on November 17, 2026, at a weighted average of $3.26 per share to cover tax obligations on the release of restricted stock units. Townsend directly held 373,483 shares after the sale, including 233,691 restricted stock units. No Rule 10b5-1 plan is reported.

Insider Townsend Richard Nolan
Role Chief Executive Officer
Sold 3,295 shs ($11K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 3,295 $3.26 $11K
Holdings After Transaction: Common Stock — 373,483 shares (Direct)
Footnotes (3)
  1. F1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
  2. F2. This transaction was executed in multiple trades at prices ranging from $3.22 to $3.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. F3. Includes 233,691 restricted stock units.
Shares sold 3,295 shares November 17, 2026; sale to cover tax obligations on restricted stock unit release
Weighted-average sale price $3.26 per share Price reported for multiple trades on November 17, 2026
Trade price range $3.22 to $3.31 per share Prices across multiple trades
Shares held after sale 373,483 shares Direct holdings after the November 17, 2026 sale; includes restricted stock units
Restricted stock units included 233,691 units Included in the reported holdings after the sale
restricted stock units financial
"release of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LXEO shares did Richard Nolan Townsend sell and at what price?

Richard Nolan Townsend sold 3,295 shares at a weighted average of $3.26 per share on November 17, 2026. The sale was executed in multiple trades at prices ranging from $3.22 to $3.31.

Why did Richard Nolan Townsend sell LXEO shares?

The sale represented shares sold to cover tax obligations on the release of restricted stock units. No Rule 10b5-1 plan is reported.

How many shares did Richard Nolan Townsend hold after the LXEO sale?

He directly held 373,483 shares after the sale, including 233,691 restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Townsend Richard Nolan

(Last)(First)(Middle)
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6

(Street)
NEW YORK NEW YORK 10010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026S(1)3,295D$3.26(2)373,483(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
2. This transaction was executed in multiple trades at prices ranging from $3.22 to $3.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. Includes 233,691 restricted stock units.
/s/ Youjin Choi, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading